Table 1.

Participant demographics and HIV disease and immunologic status at the time of PET imaging study enrollment.

ID	Group	ART regimen	Days on ARTa	Viral loadb	CD4+ T cell countc	Lymph node samplingd
V1	Viremic	None	–	74,534	192	Y
V2	Viremic	None	–	19,872	243	Y
V3	Viremic	None	–	789,705	36	N
V4	Viremic	None	–	106,994	19	Y
V5	Viremic	None	–	3499	500	Y
A1	ART	ABC/3TC/DTG	105	NDe	578	Y
A2	ART	TAF/FTC/EVG/c	3150	ND	526	N
A3	ART	ABC/3TC/DTG	8509	ND	621	N
A4	ART	RPV/DTG	640	ND	650	N
A5	ART	TAF/FTC/EGV/DRV/c	6863	ND	527	N
C1	Control	–	–	–	1503	–
C2	Control	–	–	–	908	–
C3	Control	–	–	–	762	–
C4	Control	–	–	–	702	–
C5	Control	–	–	–	158	–

ART antiretroviral therapy, ABC abacavir, DTG dolutegravir, 3TC lamivudine, TAF tenofovir alafenamide, RPV rilpivirine, EVG elvitegravir, c cobicistat, DRV darunavir.

^aContinuous ART since last viremic episode.

^bPlasma HIV-1 RNA copies/mL.

^cCells/mL.

^dParticipant provided additional consent to under inguinal lymph node needle biopsy.

^ePlasma HIV-1 RNA not detected (limit of quantification 40 copies/mL).